Clinical Trials for Mesothelioma Patients: Pazopanib Patient Concurrent Therapy

Read the patient concurrent therapy characteristics criteria about a current clinical trial being conducted to study the effects of Pazopanib for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Prior Concurrent Therapy:

• See Disease Characteristics
• No more than 1 prior systemic therapy for malignant pleural mesothelioma
• No ancillary therapy considered investigational within the past 4 weeks
• No major surgery (i.e., laparotomy) or open biopsy within the past 4 weeks*
• No minor surgery within the past 2 weeks*
• Prior palliative radiotherapy allowed o No prior palliative radiotherapy to the chest except for a maximum of 3 fractions of radiotherapy for superior vena cava syndrome
• No concurrent therapeutic Warfarin o Low molecular-weight heparin or prophylactic low-dose Warfarin allowed
• No other concurrent chemotherapy, immunotherapy, hormonal therapy, or radiotherapy
• No concurrent medications that act through the CYP450 system
• No concurrent combination antiretroviral therapy for HIV-positive patients NOTE: *Insertion of a vascular access device is not considered major or minor surgery

Courtesy of ClinicalTrials.gov.

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney